What are the components of Xultophy?

Xultophy is a combination medication that specifically includes liraglutide, which is a GLP-1 receptor agonist, and insulin degludec, a long-acting insulin. This combination is designed to enhance glycemic control in adults with type 2 diabetes.

Liraglutide works by stimulating insulin secretion in response to meals, reducing glucagon release, and slowing gastric emptying, which collectively help to lower blood sugar levels. Insulin degludec provides a steady and prolonged insulin action, allowing for better management of blood glucose throughout the day and night.

The combination of these two agents in Xultophy is particularly beneficial as it addresses diabetes management through two different mechanisms of action—enhancing insulin secretion and improving insulin sensitivity—leading to more effective overall glucose control.

The other options listed do not correctly represent the components of Xultophy, as they either combine medications that do not belong to this specific product or mix unrelated agents that target different aspects of diabetes management.